REDS: Q3 2025 saw 38% sales growth, improved EBIT, and key product launches amid global expansion

About this update from Redsense Medical Ab

Net sales rose 38% year-over-year in Q3 2025, with the US driving growth and operating losses narrowing. The company advanced regulatory and market expansion efforts, but faces ongoing currency and trade risks. Cash position remains strong at KSEK 12,239.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Redsense Medical Ab